New CRISPR method makes it possible to control protein production in cells

The speed at which a cell produces proteins is a decisive factor in determining whether it divides, specializes or retains ...

Optimizing RNA design with AI and an Ising machine: Encoding matters

RNA has emerged as one of the most promising molecules in modern medicine, enabling advances from mRNA vaccines and gene ...
GEN - Genetic Engineering and Biotechnology News

The Quest for Large-Scale DNA

As genome editing therapies move through clinical trials to regulatory approval, scientists continue the quest for the holy ...

ProQR Raises $59 Million in Equity Offering and Eli Lilly Private Placement

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.

ProQR Reports Positive Phase 1 Data Validating Axiomer RNA Editing Platform

Detailed price information for Proqr Therapeutics (PRQR-Q) from The Globe and Mail including charting and trades.

ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform

Data from ongoing Phase 1 study of AX-0810 in healthy volunteers demonstrated dose-dependent target engagement on all key biomarkers in the ...
TMCnet

ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement

ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer ™  RNA ...